The Semaglutide And Exenatide Market continues to expand as endocrinologists, cardiologists, and obesity medicine specialists increasingly recognize the transformative impact of GLP-1 receptor agonists on metabolic disease management and cardiovascular risk reduction. With semaglutide and exenatide representing two of the most established and widely studied agents in this drug class, the demand...